TG4010 to be retired
January 2020

STRASBOURG, France—A Phase 2 trial of Transgene’s TG4010 in combination with chemotherapy and Opdivo failed to reach its primary endpoint of overall response rate, the company announced last month. The trial was evaluating this regimen as a first-line treatment for patients with advanced non-squamous non-small cell lung cancer with low-to-no expression of PD-L1. Given the results, Transgene will be halting development of TG4010. Transgene Chairman and CEO Dr. Philippe Archinard said the company was “very disappointed” with the results, but noted that the company is moving forward with other compounds, such as TG4001, TG4050 and TG6002, among others: “These multiple advances give me great confidence that Transgene is well placed to demonstrate and deliver the potential of its novel therapeutic vaccines and oncolytic viruses designed to improve the treatment of solid tumors.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.